Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACET | US
-0.17
-2.28%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
06/03/2026
7.29
7.30
7.37
7.06
Adicet Bio Inc. a clinical stage biotechnology company discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting facilitate innate and adaptive anti-tumor immune response and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001 which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002 which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925 a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio Inc. is based in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
61.2%1 month
77.3%3 months
66.2%6 months
77.4%-
-
0.51
0.08
0.07
-1.21
2.14
0.82
-121.50M
600.70M
600.70M
-
-
-
-100.00
-57.91
9.15
5.34
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.95
Range1M
1.94
Range3M
8.59
Rel. volume
0.32
Price X volume
414.23K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals Inc | IRWD | Drug Manufacturers-Specialty & Generic | 3.5 | 559.09M | -3.31% | 55.00 | -199.01% |
| Elite Pharmaceuticals Inc | ELTP | Drug Manufacturers-Specialty & Generic | 0.392 | 422.34M | -2.00% | 29.50 | 0.00% |
| Aquestive Therapeutics Inc | AQST | Drug Manufacturers-Specialty & Generic | 4.22 | 384.27M | -0.94% | n/a | -329.45% |
| Organogenesis Holdings Inc | ORGO | Drug Manufacturers-Specialty & Generic | 2.79 | 369.88M | -3.79% | n/a | 42.12% |
| Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 2.47 | 361.57M | -3.52% | n/a | 36.36% |
| Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 5.53 | 348.91M | -2.30% | n/a | 656.27% |
| Cipher Pharmaceuticals Inc | CPHRF | Drug Manufacturers-Specialty & Generic | 10.54 | 269.43M | -3.13% | 13.22 | 0.00% |
| Solid Biosciences Inc | SLDB | Drug Manufacturers-Specialty & Generic | 6.75 | 260.52M | 20.32% | n/a | 13.09% |
| LFCR | LFCR | Drug Manufacturers-Specialty & Generic | 6.96 | 256.32M | -0.85% | 40.08 | -3248.43% |
| Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 11.34 | 202.92M | 6.98% | n/a | 0.60% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Ennis Inc | EBF | Building Products & Equipment | 21.31 | 554.14M | 0.47% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.77 | 515.16M | -6.26% | n/a | 1.50% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.91 | 374.57M | -2.74% | n/a | 174.23% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.36 | 332.15M | -5.03% | n/a | 3644.76% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 19.73 | 327.66M | -3.76% | 34.27 | 26.82% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.09 | 246.15M | -2.48% | 13.23 | 0.00% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 15.52 | 173.17M | -11.82% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.86 | 158.32M | -6.01% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 41.85 | 120.19M | 2.07% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.25 | 101.81M | -0.95% | 9.09 | 39.79% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.21 | 24.85 | Cheaper |
| Ent. to Revenue | 2.14 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 0.51 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 66.20 | 65.24 | Par |
| Debt to Equity | 0.08 | -1.88 | Expensive |
| Debt to Assets | 0.07 | 0.48 | Cheaper |
| Market Cap | 600.70M | 3.71B | Emerging |